RRM2 is also related to poor prognosis and overexpressed in a variety of human cancers, such as breast cancer (13), lung cancer (14), colorectal cancer (15), glioma (16), renal cell carcinoma (17), and prostate cancer (10). Here, RRM2 is linked to lung carcinoma.